Skip to main content

Advertisement

Log in

Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD

  • ORIGINAL PAPER
  • Published:
European Archives of Psychiatry and Clinical Neuroscience Aims and scope Submit manuscript

Abstract

In this study, we investigated whether availability of striatal dopamine transporter (DAT) may have an influence on the response of adult patients with attention deficit hyperactivity disorder (ADHD) on methylphenidate (MPH). In 18 non–smoking and non–medicated adult patients with ADHD, availability of DAT was measured with [99mTc] TRODAT–1 SPECT. Then, the patients received methylphenidate (MPH), individually titrated up to 60 mg per day. Ten weeks later, clinical improvement was rated by Clinical Global Impressions scale. In all, 6 patients were classified as non–responders, and 12 responded to MPH. From the non–responders, 5 presented with a DAT availability below that of normal controls of the same age, whereas in the group of responders all patients had elevated DAT availability. There was a significant negative correlation between values for global clinical improvement and striatal DAT availability. In conclusion, ADHD patients with low DAT availability seem not to respond to therapy with MPH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Al Younis ICH (2002) Attention deficit hyperactivity disorder: neuroimaging before and after treatment with methylphenidate in children. J Nucl Med 43(Suppl 5):347P

    Google Scholar 

  2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. American Psychiatric Association, Washington DC

  3. Castellanos FX, Tannock R (2002) Neuroscience of attentiondeficit/ hyperactivity disorder: the search for endophenotypes. Nature Rev Neurosci 3:617–628

    CAS  Google Scholar 

  4. Cheon KA, Ryu YH, Kim JW, Cho DY (2005) The homozygosity for 10–repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate. Eur Neuropsychopharmacol 15:95–101

    Article  PubMed  CAS  Google Scholar 

  5. Cheon K–A, Ryu YH, Kim Y–K, Namkoong K, Kim C–H, Lee JD (2003) Dopamine transporter availability in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder. Eur J Nucl Med 30:306–311

    Article  CAS  Google Scholar 

  6. Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ (1999) Dopamine transporter availability in patients with attention deficit hyperactivity disorder. Lancet 354:2132–2133

    Article  PubMed  CAS  Google Scholar 

  7. Dresel S, Krause J, Krause KH, LaFougere C, Brinkbaumer K, Kung HF, Hahn K, Tatsch K (2000) Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT–1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med 27:518–1524

    Article  Google Scholar 

  8. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, Sklar P (2005) Molecular genetics of attention–deficit/ hyperactivity disorder. Biol Psychiatry 57:1313–1323

    Article  PubMed  CAS  Google Scholar 

  9. Guy W (2000) Clinical Global Impressions Scale [CGI] (1976). In: American Psychiatric Association. Task Force for the Handbook of Psychiatric Measures (ed), Handbook of psychiatric measures. American Psychiatric Association, Washington DC, pp 100–102

  10. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K (2000) Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 285:107–110

    Article  PubMed  CAS  Google Scholar 

  11. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K, Ackenheil M (2002) Stimulant–like action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder. Int J Neuropsychopharmacol 5:111–113

    Article  PubMed  CAS  Google Scholar 

  12. Krause KH, Dresel SH, Krause J, la Fougere C, Ackenheil M (2003) The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neurosci Biobehav Rev 27:605–613

    Article  PubMed  CAS  Google Scholar 

  13. Madras BK, Miller GM, Fischman AJ (2005) The dopamine transporter and attention–deficit/hyperactivity disorder. Biol Psychiatry 57:1397–1409

    Article  PubMed  CAS  Google Scholar 

  14. Mozley PD, Acton PD, Barraclough ED, Plossl K, Gur RC, Alavi A, Mathur A, Saffer J, Kung HF (1999) Effects of age on dopamine transporters in healthy humans. J Nucl Med 40:1812–1817

    PubMed  CAS  Google Scholar 

  15. Retz W, Retz–Junginger P, Hengesch G, Schneider M, Thome J, Pajonk FG, Salahi–Disfan A, Rees O, Wender PH, Rösler M (2004) Psychometric and psychopathological characterization of young male prison inmates with and without attention deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 254:201–208

    PubMed  Google Scholar 

  16. Rösler M, Retz W, Retz–Junginger P, Hengesch G, Schneider M, Supprian T, Schwitzgebel P, Pinhard K, Dovi–Akue N, Wender P, Thome J (2004) Prevalence of attention deficit–/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. Eur Arch Psychiatry Clin Neurosci 254:365–371

    PubMed  Google Scholar 

  17. Roman T, Szobot C, Martins S, Biederman J, Rohde LA, Hutz MH (2002) Dopamine transporter gene and response to methylphenidate in attention deficit/hyperactivity disorder. Pharmacogenetics 12:497–499

    Article  PubMed  CAS  Google Scholar 

  18. Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, Mick E, Aleardi M, Herzig K, Faraone S (2005) A large, doubleblind, randomized clinical trial of methylphenidate in the treatment of adults with attention–deficit/hyperactivity disorder. Biol Psychiatry 57:456–463

    PubMed  CAS  Google Scholar 

  19. van Dyck CH, Quinlan DM, Cretella LM, Staley JK, Malison RT, Baldwin RM, Seibyl JP, Innis RB (2002) Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder. Am J Psychiatry 159:309–312

    Article  PubMed  Google Scholar 

  20. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, Hitzemann R, Smith G, Fields SD, Gur R (1996) Dopamine transporters decrease with age. J Nucl Med 37:554–559

    PubMed  CAS  Google Scholar 

  21. Winsberg BG, Comings DE. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response (1999) J Am Acad Child Adolesc Psychiatry 38:1474–1477

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. Krause M.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krause, J., la Fougere, C., Krause, KH. et al. Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. Eur Arch Psychiatry Clin Neurosci 255, 428–431 (2005). https://doi.org/10.1007/s00406-005-0602-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00406-005-0602-x

Key words

Navigation